GSK plc announced a 2% increase in Q1 2023 sales to £6.95 billion, with significant growth in earnings and operating profit. The company highlights strong portfolio performance and...
GSK plc reports a 2% increase in Q1 2023 sales to £6.95 billion, with significant growth in EPS and operating profit. CEO Emma Walmsley emphasizes the strength of the Specialty Med...
GSK plc announced a 2% increase in Q1 2023 sales to £6.95 billion, with a 55% surge in EPS and a 49% rise in operating profit. CEO Emma Walmsley emphasized the company's strong por...
GSK plc reports a 2% increase in Q1 2023 sales to £6.95 billion, with significant growth in EPS and operating profit. CEO Emma Walmsley underscores the company's strong portfolio a...
GSK plc reports a 2% increase in Q1 sales to £6.95 billion, with significant growth in earnings and operating profit. CEO Emma Walmsley highlights the company's strong portfolio an...
GSK plc reports a 2% increase in Q1 2023 sales to £6.95 billion, with core EPS up 4% and operating profit soaring by 49%. CEO Emma Walmsley highlights the strength of the Specialty...
GSK plc reports a 2% increase in Q1 2023 sales to £6.95 billion, with a 55% surge in EPS and a 49% increase in operating profit. CEO Emma Walmsley emphasizes the company's strong p...
GSK plc announced a 2% increase in Q1 2023 sales to £6.95 billion, with significant growth in earnings per share and operating profit. CEO Emma Walmsley highlighted the strength of...
GSK plc announced a 2% increase in Q1 sales, totaling £6.95 billion, demonstrating resilience in a challenging market. More updates on their performance and strategies are forthcom...
GSK plc has agreed to acquire IDRx, Inc. for up to $1.15 billion, including a highly selective KIT tyrosine kinase inhibitor, IDRX-42, for GIST treatment, promising to address a si...
